S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Critical asset just had biggest fall on record (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
Critical asset just had biggest fall on record (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
66,000% upside on tiny biotech? (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:COCP

Cocrystal Pharma (COCP) Stock Price, News & Analysis

$1.44
-0.01 (-0.69%)
(As of 02/23/2024 ET)
Today's Range
$1.38
$1.51
50-Day Range
$1.44
$1.89
52-Week Range
$1.33
$3.29
Volume
8,245 shs
Average Volume
10,089 shs
Market Capitalization
$14.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Cocrystal Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
594.4% Upside
$10.00 Price Target
Short Interest
Healthy
0.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.39mentions of Cocrystal Pharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.01) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

520th out of 942 stocks

Pharmaceutical Preparations Industry

234th out of 428 stocks


COCP stock logo

About Cocrystal Pharma Stock (NASDAQ:COCP)

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

COCP Stock Price History

COCP Stock News Headlines

Cocrystal Pharma Inc (COCP)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Cocrystal Pharma Inc COCP
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Recap: Cocrystal Pharma Q3 Earnings
Analyst Ratings for Cocrystal Pharma
Cocrystal Pharma (COCP) Receives a Buy from H.C. Wainwright
Noble Financial Keeps Their Buy Rating on Cocrystal Pharma (COCP)
See More Headlines
Receive COCP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cocrystal Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/24/2024
Next Earnings (Estimated)
4/03/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:COCP
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+594.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,840,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
$0.16 per share
Book Value
$4.87 per share

Miscellaneous

Free Float
7,624,000
Market Cap
$14.65 million
Optionable
Not Optionable
Beta
1.38
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Roger D. Kornberg Ph.D. (Age 77)
    Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board
    Comp: $125k
  • Dr. Sam Lee Ph.D. (Age 64)
    Co-Founder, Co-CEO & President
    Comp: $521.38k
  • Mr. James J. Martin CPA (Age 57)
    M.B.A., Co-CEO, CFO & Corporate Secretary
    Comp: $521.38k














COCP Stock Analysis - Frequently Asked Questions

Should I buy or sell Cocrystal Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cocrystal Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COCP shares.
View COCP analyst ratings
or view top-rated stocks.

What is Cocrystal Pharma's stock price target for 2024?

1 brokerages have issued 12 month target prices for Cocrystal Pharma's shares. Their COCP share price targets range from $10.00 to $10.00. On average, they expect the company's share price to reach $10.00 in the next year. This suggests a possible upside of 594.4% from the stock's current price.
View analysts price targets for COCP
or view top-rated stocks among Wall Street analysts.

How have COCP shares performed in 2024?

Cocrystal Pharma's stock was trading at $1.7222 at the beginning of 2024. Since then, COCP stock has decreased by 16.4% and is now trading at $1.44.
View the best growth stocks for 2024 here
.

Are investors shorting Cocrystal Pharma?

Cocrystal Pharma saw a increase in short interest during the month of January. As of January 31st, there was short interest totaling 2,600 shares, an increase of 225.0% from the January 15th total of 800 shares. Based on an average trading volume of 18,400 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the stock are short sold.
View Cocrystal Pharma's Short Interest
.

When is Cocrystal Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024.
View our COCP earnings forecast
.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) released its quarterly earnings data on Monday, November, 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.48).

When did Cocrystal Pharma's stock split?

Cocrystal Pharma's stock reverse split before market open on Tuesday, October 11th 2022. The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cocrystal Pharma investors own include Moderna (MRNA), Hello Group (MOMO), Intra-Cellular Therapies (ITCI), Impala Platinum (IMPUY), GenMark Diagnostics (GNMK), Gevo (GEVO), Auxly Cannabis Group (CBWTF), Bionano Genomics (BNGO), Blink Charging (BLNK) and Bilibili (BILI).

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COCP) was last updated on 2/25/2024 by MarketBeat.com Staff